LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Biotechnology

Healthcare
$40.06 -1.30%

-$0.39 today

Market cap
$1.30B
Beta
0.71
P/E (TTM)
-21.4
EPS (TTM)
-$1.39
52W Low $13.36High $33.47

Volume 0.36M

Average 0.23M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$35.21M

FY 2025 · Annual

Investing Cash Flow

-$39.89M

FY 2025 · Annual

Financing Cash Flow

$302.56M

FY 2025 · Annual

+689.7% YoY

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.35M)(6.28M)(63.1M)(25.21M)
Depreciation & Amortization2K4K91K321K
Deferred Income Tax0000
Stock-Based Compensation431K295K3.16M0
Change in Working Capital86K(1.31M)3.31M(13.65M)
Accounts Receivables0(154K)114K(268K)
Inventory0000
Accounts Payables000(910K)
Other Working Capital86K(1.16M)3.2M(12.47M)
Other Non-Cash Items11.1M(4.81M)3.49M3.33M
Operating Cash Flow(2.73M)(12.09M)(53.05M)(35.21M)
Capital Expenditures0(25K)(769K)(52K)
Acquisitions (Net)0000
Purchases of Investments0(33.99M)(29.75M)(44.84M)
Sales of Investments123K6M53.75M5M
Other Investing Activities0000
Investing Cash Flow123K(28.01M)23.23M(39.89M)
Debt Repayment25.01M725K00
Common Stock Issued000302.56M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(2.95M)(2.05M)(1.69M)0
Financing Cash Flow22.96M33.68M38.32M302.56M
Effect of Forex Changes000(272K)
Net Change in Cash20.36M(6.43M)8.5M227.2M
Free Cash Flow(2.73M)(12.12M)(53.82M)(35.26M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$25.2M
+ D&A$321.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$13.7M
+ Other Non-Cash$3.3M
= Operating Cash Flow-$35.2M
- Capex-$52.0K
= Free Cash Flow-$35.3M

Analysis

FY2025 free cash flow is -$35.3M. FCF conversion is 139.9% of net income. Operating cash flow was -$35.2M, with capex of -$52.0K. The largest bridge item is Working Capital at -$13.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 13, 2026
SC 13G/ASC 13G/A filingOct 13, 2026
4Statement of changes in beneficial ownershipOct 13, 2026

Does LBRX generate free cash flow?

LB Pharmaceuticals Inc Common Stock (LBRX) generated -$35.26M of free cash flow in fiscal 2025.

How much operating cash flow does LBRX produce?

Operating cash flow was -$35.21M, before capital expenditures of $52,000.00.